factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 435-444 | 435-444 | T29 | underwent | TREATS | 435 | 444 | preserve | 454-468 | 462-468 | T26 | gastric bypass | TherapeuticOrPreventiveProcedure | 454 | 468 | preserve | 412-419 | 412-419 | T25 | obesity | DiseaseOrSyndrome | 412 | 419 | A1 | In this article, we present a patient with super/super obesity (61 kg/m2) who underwent Rouxen-Y gastric bypass using the laparoscopic approach. | 350-507 | 350 | 507 | In this article, we present a patient with super/super @OBJECT$ (61 kg/m2) who @PREDICAT$ Rouxen-Y @SUBJECT$ using the laparoscopic approach. |
Fact | preserve | 248-252 | 248-252 | T22 | with | PROCESS_OF | 248 | 252 | preserve | 255-258 | 255-258 | T16 | BMI | ClinicalAttribute | 255 | 258 | preserve | 239-247 | 239-247 | T15 | patients | PatientOrDisabledGroup | 239 | 247 | A2 | This procedure has been generally limited to patients with a BMI <60 kg/m2 due to the possible technical limitations of the laparoscopic instruments. | 188-349 | 188 | 349 | This procedure has been generally limited to @OBJECT$ @PREDICAT$ a @SUBJECT$ <60 kg/m2 due to the possible technical limitations of the laparoscopic instruments. |
Fact | preserve | 38-41 | 38-41 | T5 | for | TREATS | 38 | 41 | preserve | 13-37 | 31-37 | T2 | Roux-en-Y gastric bypass | TherapeuticOrPreventiveProcedure | 13 | 37 | preserve | 54-61 | 54-61 | T4 | obesity | DiseaseOrSyndrome | 54 | 61 | A3 | Laparoscopic Roux-en-Y gastric bypass for super/super obesity. | 0-62 | 0 | 62 | Laparoscopic @SUBJECT$ @PREDICAT$ super/super @OBJECT$ . |
Fact | preserve | 388-392 | 388-392 | T28 | with | PROCESS_OF | 388 | 392 | preserve | 412-419 | 412-419 | T25 | obesity | DiseaseOrSyndrome | 412 | 419 | preserve | 380-387 | 380-387 | T23 | patient | PatientOrDisabledGroup | 380 | 387 | A4 | In this article, we present a patient with super/super obesity (61 kg/m2) who underwent Rouxen-Y gastric bypass using the laparoscopic approach. | 350-507 | 350 | 507 | In this article, we present a @OBJECT$ @PREDICAT$ super/super @SUBJECT$ (61 kg/m2) who underwent Rouxen-Y gastric bypass using the laparoscopic approach. |
Fact | preserve | 268-277 | 268-277 | T33 | treatment | TREATS | 268 | 277 | preserve | 255-267 | 255-267 | T18 | troglitazone | OrganicChemical | 255 | 267 | preserve | 309-326 | 309-326 | T22 | insulin-resistant | PathologicFunction | 309 | 326 | A1 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of @SUBJECT$ @PREDICAT$ in a severely hyperandrogenic, @OBJECT$ woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 794-816 | 807-816 | T74 | troglitazone treatment | USES | 794 | 816 | preserve | 807-816 | 807-816 | T63 | treatment | TherapeuticOrPreventiveProcedure | 807 | 816 | preserve | 794-806 | 794-806 | T62 | troglitazone | OrganicChemical | 794 | 806 | A2 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. | 685-941 | 685 | 941 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, @OBJECT$ @PREDICAT$ @SUBJECT$ resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. |
Fact | preserve | 771-792 | 785-792 | T73 | dexamethasone therapy | USES | 771 | 792 | preserve | 785-792 | 785-792 | T61 | therapy | TherapeuticOrPreventiveProcedure | 785 | 792 | preserve | 771-784 | 771-784 | T60 | dexamethasone | PharmacologicSubstance | 771 | 784 | A4 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. | 685-941 | 685 | 941 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and @OBJECT$ @PREDICAT$ @SUBJECT$ , troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. |
Fact | preserve | 255-277 | 268-277 | T32 | troglitazone treatment | USES | 255 | 277 | preserve | 268-277 | 268-277 | T19 | treatment | TherapeuticOrPreventiveProcedure | 268 | 277 | preserve | 255-267 | 255-267 | T18 | troglitazone | OrganicChemical | 255 | 267 | A5 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of @OBJECT$ @PREDICAT$ @SUBJECT$ in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 1421-1447 | 1440-1447 | T113 | oral contraceptive therapy | USES | 1,421 | 1,447 | preserve | 1440-1447 | 1440-1447 | T106 | therapy | TherapeuticOrPreventiveProcedure | 1,440 | 1,447 | preserve | 1421-1439 | 1426-1439 | T105 | oral contraceptive | PharmacologicSubstance | 1,421 | 1,439 | A7 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus @OBJECT$ @PREDICAT$ @SUBJECT$ and dexamethasone. |
Fact | preserve | 605-609 | 605-609 | T55 | with | PROCESS_OF | 605 | 609 | preserve | 620-627 | 620-627 | T51 | obesity | DiseaseOrSyndrome | 620 | 627 | preserve | 599-604 | 599-604 | T49 | woman | PopulationGroup | 599 | 604 | A8 | PATIENT(S): A 28-year-old African-American woman with excessive obesity (body mass index = 42 kg/m2) and HAIR-AN syndrome. | 550-684 | 550 | 684 | PATIENT(S): A 28-year-old African-American @OBJECT$ @PREDICAT$ excessive @SUBJECT$ (body mass index = 42 kg/m2) and HAIR-AN syndrome. |
Fact | preserve | 268-277 | 268-277 | T33 | treatment | TREATS | 268 | 277 | preserve | 255-267 | 255-267 | T18 | troglitazone | OrganicChemical | 255 | 267 | preserve | 327-332 | 327-332 | T23 | woman | PopulationGroup | 327 | 332 | A9 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of @SUBJECT$ @PREDICAT$ in a severely hyperandrogenic, insulin-resistant @OBJECT$ with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 339-343 | 339-343 | T35 | with | PROCESS_OF | 339 | 343 | preserve | 344-364 | 355-364 | T24 | acanthosis nigricans | DiseaseOrSyndrome | 344 | 364 | preserve | 327-332 | 327-332 | T23 | woman | PopulationGroup | 327 | 332 | A11 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant @OBJECT$ @PREDICAT$ @SUBJECT$ (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 771-792 | 785-792 | T70 | dexamethasone therapy | ISA | 771 | 792 | preserve | 771-784 | 771-784 | T60 | dexamethasone | PharmacologicSubstance | 771 | 784 | preserve | 785-792 | 785-792 | T61 | therapy | TherapeuticOrPreventiveProcedure | 785 | 792 | A13 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. | 685-941 | 685 | 941 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and @SUBJECT$ @PREDICAT$ @OBJECT$ , troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. |
Fact | preserve | 463-484 | 477-484 | T31 | dexamethasone therapy | ISA | 463 | 484 | preserve | 463-476 | 463-476 | T28 | dexamethasone | PharmacologicSubstance | 463 | 476 | preserve | 477-484 | 477-484 | T29 | therapy | TherapeuticOrPreventiveProcedure | 477 | 484 | A14 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1523-1534 | 1523-1534 | T128 | attenuation | TREATS | 1,523 | 1,534 | preserve | 1501-1510 | 1501-1510 | T116 | treatment | TherapeuticOrPreventiveProcedure | 1,501 | 1,510 | preserve | 1543-1559 | 1543-1559 | T118 | hyperinsulinemia | DiseaseOrSyndrome | 1,543 | 1,559 | A15 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): Troglitazone @SUBJECT$ resulted in @PREDICAT$ of both @OBJECT$ and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 1482-1510 | 1501-1510 | T127 | Troglitazone treatment | USES | 1,482 | 1,510 | preserve | 1501-1510 | 1501-1510 | T116 | treatment | TherapeuticOrPreventiveProcedure | 1,501 | 1,510 | preserve | 1482-1494 | 1482-1494 | T115 | Troglitazone | OrganicChemical | 1,482 | 1,494 | A17 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): @OBJECT$ @PREDICAT$ @SUBJECT$ resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 255-277 | 268-277 | T30 | troglitazone treatment | ISA | 255 | 277 | preserve | 255-267 | 255-267 | T18 | troglitazone | OrganicChemical | 255 | 267 | preserve | 268-277 | 268-277 | T19 | treatment | TherapeuticOrPreventiveProcedure | 268 | 277 | A18 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of @SUBJECT$ @PREDICAT$ @OBJECT$ in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 1302-1306 | 1302-1306 | T111 | with | PROCESS_OF | 1,302 | 1,306 | preserve | 1328-1336 | 1328-1336 | T102 | syndrome | DiseaseOrSyndrome | 1,328 | 1,336 | preserve | 1296-1301 | 1296-1301 | T99 | woman | PopulationGroup | 1,296 | 1,301 | A19 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a @OBJECT$ @PREDICAT$ severe HAIR-AN @SUBJECT$ whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. |
Fact | preserve | 86-97 | 92-97 | T12 | obese woman | PROCESS_OF | 86 | 97 | preserve | 86-91 | 86-91 | T6 | obese | DiseaseOrSyndrome | 86 | 91 | preserve | 92-97 | 92-97 | T7 | woman | PopulationGroup | 92 | 97 | A20 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. | 0-178 | 0 | 178 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an @SUBJECT$ @PREDICAT$ @OBJECT$ with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. |
Fact | preserve | 1380-1390 | 1380-1390 | T112 | normalized | AFFECTS | 1,380 | 1,390 | preserve | 1407-1409 | 1407-1409 | T104 | LA | AminoAcidPeptideOrProtein | 1,407 | 1,409 | preserve | 1343-1359 | 1343-1359 | T103 | hyperandrogenism | DiseaseOrSyndrome | 1,343 | 1,359 | A21 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose @OBJECT$ previously could be @PREDICAT$ only with depot @SUBJECT$ plus oral contraceptive therapy and dexamethasone. |
Fact | preserve | 1587-1589 | 1587-1589 | T131 | in | PROCESS_OF | 1,587 | 1,589 | preserve | 1564-1580 | 1564-1580 | T119 | hyperandrogenism | DiseaseOrSyndrome | 1,564 | 1,580 | preserve | 1599-1604 | 1599-1604 | T121 | woman | PopulationGroup | 1,599 | 1,604 | A23 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and @SUBJECT$ @PREDICAT$ an obese @OBJECT$ with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 723-727 | 723-727 | T72 | with | USES | 723 | 727 | preserve | 702-722 | 711-722 | T57 | Androgen suppression | TherapeuticOrPreventiveProcedure | 702 | 722 | preserve | 734-736 | 734-736 | T58 | LA | AminoAcidPeptideOrProtein | 734 | 736 | A24 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. | 685-941 | 685 | 941 | INTERVENTION(S): @SUBJECT$ @PREDICAT$ depot @OBJECT$ plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. |
Fact | preserve | 1587-1589 | 1587-1589 | T131 | in | PROCESS_OF | 1,587 | 1,589 | preserve | 1543-1559 | 1543-1559 | T118 | hyperinsulinemia | DiseaseOrSyndrome | 1,543 | 1,559 | preserve | 1599-1604 | 1599-1604 | T121 | woman | PopulationGroup | 1,599 | 1,604 | A25 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both @SUBJECT$ and hyperandrogenism @PREDICAT$ an obese @OBJECT$ with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 463-484 | 477-484 | T36 | dexamethasone therapy | USES | 463 | 484 | preserve | 477-484 | 477-484 | T29 | therapy | TherapeuticOrPreventiveProcedure | 477 | 484 | preserve | 463-476 | 463-476 | T28 | dexamethasone | PharmacologicSubstance | 463 | 476 | A26 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 16-25 | 16-25 | T11 | treatment | TREATS | 16 | 25 | preserve | 61-73 | 61-73 | T5 | troglitazone | OrganicChemical | 61 | 73 | preserve | 92-97 | 92-97 | T7 | woman | PopulationGroup | 92 | 97 | A28 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. | 0-178 | 0 | 178 | Pregnancy after @PREDICAT$ with the insulin-sensitizing agent @SUBJECT$ in an obese @OBJECT$ with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. |
Fact | preserve | 1291-1293 | 1291-1293 | T110 | in | PROCESS_OF | 1,291 | 1,293 | preserve | 1185-1207 | 1198-1207 | T93 | intrauterine pregnancy | OrganismFunction | 1,185 | 1,207 | preserve | 1296-1301 | 1296-1301 | T99 | woman | PopulationGroup | 1,296 | 1,301 | A29 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an @SUBJECT$ after 5 months of treatment with troglitazone, an insulin-sensitizing agent, @PREDICAT$ a @OBJECT$ with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. |
Fact | preserve | 1593-1604 | 1599-1604 | T130 | obese woman | PROCESS_OF | 1,593 | 1,604 | preserve | 1593-1598 | 1593-1598 | T120 | obese | DiseaseOrSyndrome | 1,593 | 1,598 | preserve | 1599-1604 | 1599-1604 | T121 | woman | PopulationGroup | 1,599 | 1,604 | A30 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an @SUBJECT$ @PREDICAT$ @OBJECT$ with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 98-102 | 98-102 | T13 | with | PROCESS_OF | 98 | 102 | preserve | 124-177 | 169-177 | T10 | insulin-resistant acanthosis nigricans syndrome | PathologicFunction | 124 | 177 | preserve | 92-97 | 92-97 | T7 | woman | PopulationGroup | 92 | 97 | A31 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. | 0-178 | 0 | 178 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese @OBJECT$ @PREDICAT$ the hyperandrogenic, @SUBJECT$ . |
Fact | preserve | 1482-1510 | 1501-1510 | T134 | Troglitazone treatment | TREATS | 1,482 | 1,510 | preserve | 1482-1494 | 1482-1494 | T115 | Troglitazone | OrganicChemical | 1,482 | 1,494 | preserve | 1564-1580 | 1564-1580 | T119 | hyperandrogenism | DiseaseOrSyndrome | 1,564 | 1,580 | A32 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): @SUBJECT$ @PREDICAT$ resulted in attenuation of both hyperinsulinemia and @OBJECT$ in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 1421-1447 | 1440-1447 | T108 | oral contraceptive therapy | ISA | 1,421 | 1,447 | preserve | 1421-1439 | 1426-1439 | T105 | oral contraceptive | PharmacologicSubstance | 1,421 | 1,439 | preserve | 1440-1447 | 1440-1447 | T106 | therapy | TherapeuticOrPreventiveProcedure | 1,440 | 1,447 | A33 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus @SUBJECT$ @PREDICAT$ @OBJECT$ and dexamethasone. |
Fact | preserve | 1236-1240 | 1236-1240 | T109 | with | USES | 1,236 | 1,240 | preserve | 1226-1235 | 1226-1235 | T95 | treatment | TherapeuticOrPreventiveProcedure | 1,226 | 1,235 | preserve | 1247-1259 | 1247-1259 | T96 | troglitazone | OrganicChemical | 1,247 | 1,259 | A34 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of treatment with troglitazone, an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. | 1134-1466 | 1,134 | 1,466 | RESULT(S): Spontaneous menses followed by an intrauterine pregnancy after 5 months of @SUBJECT$ @PREDICAT$ @OBJECT$ , an insulin-sensitizing agent, in a woman with severe HAIR-AN syndrome whose hyperandrogenism previously could be normalized only with depot LA plus oral contraceptive therapy and dexamethasone. |
Fact | preserve | 309-332 | 327-332 | T34 | insulin-resistant woman | PROCESS_OF | 309 | 332 | preserve | 309-326 | 309-326 | T22 | insulin-resistant | PathologicFunction | 309 | 326 | preserve | 327-332 | 327-332 | T23 | woman | PopulationGroup | 327 | 332 | A35 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, @SUBJECT$ @PREDICAT$ @OBJECT$ with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 1482-1510 | 1501-1510 | T126 | Troglitazone treatment | ISA | 1,482 | 1,510 | preserve | 1482-1494 | 1482-1494 | T115 | Troglitazone | OrganicChemical | 1,482 | 1,494 | preserve | 1501-1510 | 1501-1510 | T116 | treatment | TherapeuticOrPreventiveProcedure | 1,501 | 1,510 | A36 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): @SUBJECT$ @PREDICAT$ @OBJECT$ resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 16-25 | 16-25 | T11 | treatment | TREATS | 16 | 25 | preserve | 61-73 | 61-73 | T5 | troglitazone | OrganicChemical | 61 | 73 | preserve | 124-177 | 169-177 | T10 | insulin-resistant acanthosis nigricans syndrome | PathologicFunction | 124 | 177 | A37 | Pregnancy after treatment with the insulin-sensitizing agent troglitazone in an obese woman with the hyperandrogenic, insulin-resistant acanthosis nigricans syndrome. | 0-178 | 0 | 178 | Pregnancy after @PREDICAT$ with the insulin-sensitizing agent @SUBJECT$ in an obese woman with the hyperandrogenic, @OBJECT$ . |
Fact | preserve | 794-816 | 807-816 | T71 | troglitazone treatment | ISA | 794 | 816 | preserve | 794-806 | 794-806 | T62 | troglitazone | OrganicChemical | 794 | 806 | preserve | 807-816 | 807-816 | T63 | treatment | TherapeuticOrPreventiveProcedure | 807 | 816 | A38 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, troglitazone treatment resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. | 685-941 | 685 | 941 | INTERVENTION(S): Androgen suppression with depot LA plus oral contraceptive and dexamethasone therapy, @SUBJECT$ @PREDICAT$ @OBJECT$ resulting in normalization of fasting insulin and testosterone, spontaneous menses, and an unassisted pregnancy. |
Fact | preserve | 1482-1510 | 1501-1510 | T134 | Troglitazone treatment | TREATS | 1,482 | 1,510 | preserve | 1482-1494 | 1482-1494 | T115 | Troglitazone | OrganicChemical | 1,482 | 1,494 | preserve | 1543-1559 | 1543-1559 | T118 | hyperinsulinemia | DiseaseOrSyndrome | 1,543 | 1,559 | A39 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): @SUBJECT$ @PREDICAT$ resulted in attenuation of both @OBJECT$ and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 268-277 | 268-277 | T33 | treatment | TREATS | 268 | 277 | preserve | 255-267 | 255-267 | T18 | troglitazone | OrganicChemical | 255 | 267 | preserve | 344-364 | 355-364 | T24 | acanthosis nigricans | DiseaseOrSyndrome | 344 | 364 | A40 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of troglitazone treatment in a severely hyperandrogenic, insulin-resistant woman with acanthosis nigricans (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. | 179-485 | 179 | 485 | OBJECTIVE: To report a case of unassisted pregnancy after 5 months of @SUBJECT$ @PREDICAT$ in a severely hyperandrogenic, insulin-resistant woman with @OBJECT$ (HAIR-AN) previously managed with depot leuprolide acetate (LA) plus oral contraceptive and dexamethasone therapy. |
Fact | preserve | 1523-1534 | 1523-1534 | T128 | attenuation | TREATS | 1,523 | 1,534 | preserve | 1501-1510 | 1501-1510 | T116 | treatment | TherapeuticOrPreventiveProcedure | 1,501 | 1,510 | preserve | 1564-1580 | 1564-1580 | T119 | hyperandrogenism | DiseaseOrSyndrome | 1,564 | 1,580 | A41 | CONCLUSION(S): Troglitazone treatment resulted in attenuation of both hyperinsulinemia and hyperandrogenism in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. | 1467-1689 | 1,467 | 1,689 | CONCLUSION(S): Troglitazone @SUBJECT$ resulted in @PREDICAT$ of both hyperinsulinemia and @OBJECT$ in an obese woman with HAIR-AN and resulted in resumption of menses and a spontaneous pregnancy. |
Fact | preserve | 1112-1125 | 1117-1125 | T71 | COPD patients | PROCESS_OF | 1,112 | 1,125 | preserve | 1112-1116 | 1112-1116 | T64 | COPD | DiseaseOrSyndrome | 1,112 | 1,116 | preserve | 1117-1125 | 1117-1125 | T65 | patients | PatientOrDisabledGroup | 1,117 | 1,125 | A1 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in @SUBJECT$ @PREDICAT$ @OBJECT$ with bronchial hyperreactivity who smoke. |
Fact | preserve | 1537-1539 | 1537-1539 | T100 | in | TREATS | 1,537 | 1,539 | preserve | 1430-1439 | 1430-1439 | T88 | Treatment | TherapeuticOrPreventiveProcedure | 1,430 | 1,439 | preserve | 1540-1569 | 1550-1569 | T95 | bronchial hyperresponsiveness | DiseaseOrSyndrome | 1,540 | 1,569 | A2 | Treatment of allergic asthmatic patients resulted in improvement of lung function (FEV1), a decrease in bronchial hyperresponsiveness and a decrease of maximal airway narrowing. | 1430-1619 | 1,430 | 1,619 | @SUBJECT$ of allergic asthmatic patients resulted in improvement of lung function (FEV1), a decrease @PREDICAT$ @OBJECT$ and a decrease of maximal airway narrowing. |
Fact | preserve | 1068-1077 | 1068-1077 | T69 | treatment | TREATS | 1,068 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1088-1098 | 1088-1098 | T63 | asthmatics | DiseaseOrSyndrome | 1,088 | 1,098 | A3 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @SUBJECT$ (FP) @PREDICAT$ in atopic @OBJECT$ and in COPD patients with bronchial hyperreactivity who smoke. |
Fact | preserve | 1452-1470 | 1462-1470 | T99 | asthmatic patients | PROCESS_OF | 1,452 | 1,470 | preserve | 1452-1461 | 1452-1461 | T90 | asthmatic | DiseaseOrSyndrome | 1,452 | 1,461 | preserve | 1462-1470 | 1462-1470 | T91 | patients | PatientOrDisabledGroup | 1,462 | 1,470 | A4 | Treatment of allergic asthmatic patients resulted in improvement of lung function (FEV1), a decrease in bronchial hyperresponsiveness and a decrease of maximal airway narrowing. | 1430-1619 | 1,430 | 1,619 | Treatment of allergic @SUBJECT$ @PREDICAT$ @OBJECT$ resulted in improvement of lung function (FEV1), a decrease in bronchial hyperresponsiveness and a decrease of maximal airway narrowing. |
Fact | preserve | 1040-1077 | 1068-1077 | T68 | fluticasone propionate (FP) treatment | USES | 1,040 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | A8 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @OBJECT$ @SUBJECT$ @PREDICAT$ in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. |
Fact | preserve | 1040-1077 | 1068-1077 | T67 | fluticasone propionate (FP) treatment | ISA | 1,040 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1068-1077 | 1068-1077 | T61 | treatment | TherapeuticOrPreventiveProcedure | 1,068 | 1,077 | A9 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @SUBJECT$ @PREDICAT$ @OBJECT$ in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. |
Fact | preserve | 380-382 | 380-382 | T23 | in | COEXISTS_WITH | 380 | 382 | preserve | 358-379 | 371-379 | T18 | inflammatory response | PathologicFunction | 358 | 379 | preserve | 383-389 | 383-389 | T19 | asthma | DiseaseOrSyndrome | 383 | 389 | A10 | The type of inflammatory response in asthma is compatible with a major contribution of professional antigen-presenting cells. | 340-477 | 340 | 477 | The type of @SUBJECT$ @PREDICAT$ @OBJECT$ is compatible with a major contribution of professional antigen-presenting cells. |
Fact | preserve | 1068-1077 | 1068-1077 | T69 | treatment | TREATS | 1,068 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1112-1116 | 1112-1116 | T64 | COPD | DiseaseOrSyndrome | 1,112 | 1,116 | A11 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @SUBJECT$ (FP) @PREDICAT$ in atopic asthmatics and in @OBJECT$ patients with bronchial hyperreactivity who smoke. |
Fact | preserve | 823-871 | 861-871 | T56 | Steroids are the most prominent medication | ISA | 823 | 871 | preserve | 823-831 | 823-831 | T44 | Steroids | Steroid | 823 | 831 | preserve | 861-871 | 861-871 | T47 | medication | PharmacologicSubstance | 861 | 871 | A12 | Steroids are the most prominent medication used in the treatment of asthma and COPD; however, the beneficial effect of steroid treatment in COPD is subject of debate. | 823-1001 | 823 | 1,001 | @SUBJECT$ @PREDICAT$ @OBJECT$ used in the treatment of asthma and COPD; however, the beneficial effect of steroid treatment in COPD is subject of debate. |
Fact | preserve | 728-741 | 728-741 | T43 | characterized | ASSOCIATED_WITH | 728 | 741 | preserve | 779-783 | 779-783 | T38 | flow | OrganismAttribute | 779 | 783 | preserve | 720-724 | 720-724 | T34 | COPD | DiseaseOrSyndrome | 720 | 724 | A13 | COPD is characterized by reduced maximum expiratory flow and slow forced emptying of the lungs. | 720-822 | 720 | 822 | @OBJECT$ is @PREDICAT$ by reduced maximum expiratory @SUBJECT$ and slow forced emptying of the lungs. |
Fact | preserve | 20-22 | 20-22 | T8 | in | COEXISTS_WITH | 20 | 22 | preserve | 7-19 | 7-19 | T1 | inflammation | PathologicFunction | 7 | 19 | preserve | 34-71 | 64-71 | T3 | chronic obstructive pulmonary disease | DiseaseOrSyndrome | 34 | 71 | A15 | Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. | 0-199 | 0 | 199 | Airway @SUBJECT$ @PREDICAT$ asthma and @OBJECT$ with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. |
Fact | preserve | 1647-1660 | 1652-1660 | T109 | COPD patients | PROCESS_OF | 1,647 | 1,660 | preserve | 1647-1651 | 1647-1651 | T103 | COPD | DiseaseOrSyndrome | 1,647 | 1,651 | preserve | 1652-1660 | 1652-1660 | T104 | patients | PatientOrDisabledGroup | 1,652 | 1,660 | A16 | During the FP-treatment of COPD patients, FEV1 remained stable, while FEV1 deteriorated significantly in the placebo group. | 1620-1749 | 1,620 | 1,749 | During the FP-treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ , FEV1 remained stable, while FEV1 deteriorated significantly in the placebo group. |
Fact | preserve | 1172-1178 | 1172-1178 | T87 | effect | AFFECTS | 1,172 | 1,178 | preserve | 1192-1201 | 1192-1201 | T77 | treatment | TherapeuticOrPreventiveProcedure | 1,192 | 1,201 | preserve | 1205-1230 | 1215-1230 | T78 | bronchial hyperreactivity | DiseaseOrSyndrome | 1,205 | 1,230 | A17 | The effect of the treatment on bronchial hyperreactivity and indices of the methacholine dose-response curve were analysed, as well as indices of inflammation of the airway mucosa with special emphasis on the antigen presenting dendritic cell. | 1168-1429 | 1,168 | 1,429 | The @PREDICAT$ of the @SUBJECT$ on @OBJECT$ and indices of the methacholine dose-response curve were analysed, as well as indices of inflammation of the airway mucosa with special emphasis on the antigen presenting dendritic cell. |
Fact | preserve | 20-22 | 20-22 | T8 | in | COEXISTS_WITH | 20 | 22 | preserve | 7-19 | 7-19 | T1 | inflammation | PathologicFunction | 7 | 19 | preserve | 23-29 | 23-29 | T2 | asthma | DiseaseOrSyndrome | 23 | 29 | A19 | Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. | 0-199 | 0 | 199 | Airway @SUBJECT$ @PREDICAT$ @OBJECT$ and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. |
Fact | preserve | 1068-1077 | 1068-1077 | T69 | treatment | TREATS | 1,068 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1117-1125 | 1117-1125 | T65 | patients | PatientOrDisabledGroup | 1,117 | 1,125 | A20 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @SUBJECT$ (FP) @PREDICAT$ in atopic asthmatics and in COPD @OBJECT$ with bronchial hyperreactivity who smoke. |
Fact | preserve | 171-175 | 171-175 | T10 | with | USES | 171 | 175 | preserve | 155-164 | 155-164 | T6 | treatment | TherapeuticOrPreventiveProcedure | 155 | 164 | preserve | 176-198 | 188-198 | T7 | fluticasone propionate | OrganicChemical | 176 | 198 | A22 | Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate. | 0-199 | 0 | 199 | Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1817-1830 | 1822-1830 | T116 | COPD patients | PROCESS_OF | 1,817 | 1,830 | preserve | 1817-1821 | 1817-1821 | T112 | COPD | DiseaseOrSyndrome | 1,817 | 1,821 | preserve | 1822-1830 | 1822-1830 | T113 | patients | PatientOrDisabledGroup | 1,822 | 1,830 | A23 | Therefore, steroid treatment may have a beneficial effect in COPD patients with bronchial hyperresponsiveness (BHR). | 1750-1878 | 1,750 | 1,878 | Therefore, steroid treatment may have a beneficial effect in @SUBJECT$ @PREDICAT$ @OBJECT$ with bronchial hyperresponsiveness (BHR). |
Fact | preserve | 1966-1979 | 1971-1979 | T134 | COPD patients | PROCESS_OF | 1,966 | 1,979 | preserve | 1966-1970 | 1966-1970 | T122 | COPD | DiseaseOrSyndrome | 1,966 | 1,970 | preserve | 1971-1979 | 1971-1979 | T123 | patients | PatientOrDisabledGroup | 1,971 | 1,979 | A24 | Since immunohistochemical analysis of bronchial biopsy specimens from asthma and COPD patients show disease-specific aspects of inflammation, the anti-inflammatory effect of FP is obtained through modulation of different cell populations in asthma and COPD. | 1879-2154 | 1,879 | 2,154 | Since immunohistochemical analysis of bronchial biopsy specimens from asthma and @SUBJECT$ @PREDICAT$ @OBJECT$ show disease-specific aspects of inflammation, the anti-inflammatory effect of FP is obtained through modulation of different cell populations in asthma and COPD. |
Fact | preserve | 1068-1077 | 1068-1077 | T69 | treatment | TREATS | 1,068 | 1,077 | preserve | 1040-1062 | 1052-1062 | T60 | fluticasone propionate | OrganicChemical | 1,040 | 1,062 | preserve | 1131-1156 | 1141-1156 | T66 | bronchial hyperreactivity | DiseaseOrSyndrome | 1,131 | 1,156 | A27 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of @SUBJECT$ (FP) @PREDICAT$ in atopic asthmatics and in COPD patients with @OBJECT$ who smoke. |
Fact | preserve | 1126-1130 | 1126-1130 | T72 | with | PROCESS_OF | 1,126 | 1,130 | preserve | 1131-1156 | 1141-1156 | T66 | bronchial hyperreactivity | DiseaseOrSyndrome | 1,131 | 1,156 | preserve | 1117-1125 | 1117-1125 | T65 | patients | PatientOrDisabledGroup | 1,117 | 1,125 | A28 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD patients with bronchial hyperreactivity who smoke. | 1002-1167 | 1,002 | 1,167 | We investigated the efficacy of fluticasone propionate (FP) treatment in atopic asthmatics and in COPD @OBJECT$ @PREDICAT$ @SUBJECT$ who smoke. |
Fact | preserve | 844-848 | 844-848 | T68 | with | PROCESS_OF | 844 | 848 | preserve | 859-873 | 865-873 | T63 | shock syndrome | PathologicFunction | 859 | 873 | preserve | 835-843 | 835-843 | T60 | patients | PatientOrDisabledGroup | 835 | 843 | A1 | It appears that optimal timing of the patients with left main shock syndrome should be guided by the relative presence of an element of ischemia or necrosis. | 791-961 | 791 | 961 | It appears that optimal timing of the @OBJECT$ @PREDICAT$ left main @SUBJECT$ should be guided by the relative presence of an element of ischemia or necrosis. |
Fact | preserve | 415-419 | 415-419 | T32 | with | PROCESS_OF | 415 | 419 | preserve | 420-423 | 420-423 | T28 | AMI | DiseaseOrSyndrome | 420 | 423 | preserve | 406-414 | 406-414 | T27 | patients | PatientOrDisabledGroup | 406 | 414 | A4 | Mortality rate was higher in the patients with AMI (15.8%) than in the patients with UAP (5.3%). | 367-469 | 367 | 469 | Mortality rate was higher in the @OBJECT$ @PREDICAT$ @SUBJECT$ (15.8%) than in the patients with UAP (5.3%). |
Fact | preserve | 736-739 | 736-739 | T57 | for | TREATS | 736 | 739 | preserve | 694-711 | 694-711 | T50 | revascularization | TherapeuticOrPreventiveProcedure | 694 | 711 | preserve | 750-758 | 750-758 | T51 | patients | PatientOrDisabledGroup | 750 | 758 | A5 | Though the surgical results for AMI with cardio-genic shock is discouraging, complete revascularization can be performed safely for the patients with UAP and uncomplicated AMI. | 602-790 | 602 | 790 | Though the surgical results for AMI with cardio-genic shock is discouraging, complete @SUBJECT$ can be performed safely @PREDICAT$ the @OBJECT$ with UAP and uncomplicated AMI. |
Fact | preserve | 262-264 | 262-264 | T21 | in | PROCESS_OF | 262 | 264 | preserve | 237-252 | 246-252 | T17 | unstable angina | DiseaseOrSyndrome | 237 | 252 | preserve | 268-276 | 268-276 | T18 | patients | PatientOrDisabledGroup | 268 | 276 | A8 | The reason for performing emergent CABG were unstable angina pectoris in 38 patients and acute myocardial infarction in 19 patients. | 186-330 | 186 | 330 | The reason for performing emergent CABG were @SUBJECT$ pectoris @PREDICAT$ 38 @OBJECT$ and acute myocardial infarction in 19 patients. |
Fact | preserve | 112-121 | 112-121 | T13 | underwent | TREATS | 112 | 121 | preserve | 131-168 | 160-168 | T11 | coronary artery bypass grafting | TherapeuticOrPreventiveProcedure | 131 | 168 | preserve | 103-111 | 103-111 | T9 | patients | PatientOrDisabledGroup | 103 | 111 | A10 | During a period of past five years, 57 patients underwent emergent coronary artery bypass grafting at our hospital. | 64-185 | 64 | 185 | During a period of past five years, 57 @OBJECT$ @PREDICAT$ emergent @SUBJECT$ at our hospital. |
Fact | preserve | 309-311 | 309-311 | T22 | in | PROCESS_OF | 309 | 311 | preserve | 281-308 | 298-308 | T19 | acute myocardial infarction | DiseaseOrSyndrome | 281 | 308 | preserve | 321-329 | 321-329 | T20 | patients | PatientOrDisabledGroup | 321 | 329 | A11 | The reason for performing emergent CABG were unstable angina pectoris in 38 patients and acute myocardial infarction in 19 patients. | 186-330 | 186 | 330 | The reason for performing emergent CABG were unstable angina pectoris in 38 patients and @SUBJECT$ @PREDICAT$ 19 @OBJECT$ . |
Fact | preserve | 2151-2158 | 2151-2158 | T110 | causing | CAUSES | 2,151 | 2,158 | preserve | 2145-2150 | 2145-2150 | T106 | drugs | PharmacologicSubstance | 2,145 | 2,150 | preserve | 2170-2184 | 2170-2184 | T108 | vasodilatation | PhysiologicFunction | 2,170 | 2,184 | A1 | This implies that in this condition long-acting calcium antagonists can be administered without untoward neurohumoral effects anytime conventional treatment needs to be complemented by drugs causing additional vasodilatation. | 1941-2185 | 1,941 | 2,185 | This implies that in this condition long-acting calcium antagonists can be administered without untoward neurohumoral effects anytime conventional treatment needs to be complemented by @SUBJECT$ @PREDICAT$ additional @OBJECT$ . |
Fact | preserve | 1114-1139 | 1125-1139 | T61 | amlodipine administration | USES | 1,114 | 1,139 | preserve | 1103-1139 | 1125-1139 | T54 | oral amlodipine administration | TherapeuticOrPreventiveProcedure | 1,103 | 1,139 | preserve | 1114-1124 | 1114-1124 | T53 | amlodipine | OrganicChemical | 1,114 | 1,124 | A2 | Measurements were performed at baseline and after 8 weeks of daily oral amlodipine administration (10 mg/d, 14 patients) or before and after an 8-week period without calcium antagonist administration (14 patients). | 1036-1262 | 1,036 | 1,262 | Measurements were performed at baseline and after 8 weeks of daily @SUBJECT$ @OBJECT$ @PREDICAT$ (10 mg/d, 14 patients) or before and after an 8-week period without calcium antagonist administration (14 patients). |
Fact | preserve | 1809-1829 | 1820-1829 | T97 | amlodipine treatment | USES | 1,809 | 1,829 | preserve | 1820-1829 | 1820-1829 | T90 | treatment | TherapeuticOrPreventiveProcedure | 1,820 | 1,829 | preserve | 1809-1819 | 1809-1819 | T89 | amlodipine | OrganicChemical | 1,809 | 1,819 | A4 | Thus, in mild heart failure amlodipine treatment does not adversely affect sympathetic activity and baroreflex control of the heart and sympathetic tone. | 1775-1940 | 1,775 | 1,940 | Thus, in mild heart failure @OBJECT$ @PREDICAT$ @SUBJECT$ does not adversely affect sympathetic activity and baroreflex control of the heart and sympathetic tone. |
Fact | preserve | 1398-1410 | 1405-1410 | T72 | plasma renin | LOCATION_OF | 1,398 | 1,410 | preserve | 1398-1404 | 1398-1404 | T67 | plasma | BodySubstance | 1,398 | 1,404 | preserve | 1405-1410 | 1405-1410 | T68 | renin | AminoAcidPeptideOrProtein | 1,405 | 1,410 | A6 | Heart rate, left ventricular ejection fraction, and plasma renin and aldosterone concentrations were not affected. | 1339-1466 | 1,339 | 1,466 | Heart rate, left ventricular ejection fraction, and @SUBJECT$ @PREDICAT$ @OBJECT$ and aldosterone concentrations were not affected. |
Fact | preserve | 1583-1609 | 1601-1609 | T83 | sympathetic nerve activity | PROCESS_OF | 1,583 | 1,609 | preserve | 1576-1609 | 1601-1609 | T78 | muscle sympathetic nerve activity | OrganOrTissueFunction | 1,576 | 1,609 | preserve | 1583-1600 | 1595-1600 | T77 | sympathetic nerve | BodyPartOrganOrOrganComponent | 1,583 | 1,600 | A8 | This was the case also for plasma norepinephrine (from 2.43+/-0.41 to 2.50+/-0.34 nmol/L, mean+/-SEM), muscle sympathetic nerve activity (from 54.4+/-5.9 to 51.0+/-4.3 bursts/min), and arterial baroreflex responses. | 1467-1694 | 1,467 | 1,694 | This was the case also for plasma norepinephrine (from 2.43+/-0.41 to 2.50+/-0.34 nmol/L, mean+/-SEM), @SUBJECT$ @OBJECT$ @PREDICAT$ (from 54.4+/-5.9 to 51.0+/-4.3 bursts/min), and arterial baroreflex responses. |
Fact | preserve | 656-678 | 670-678 | T45 | heart failure patients | PROCESS_OF | 656 | 678 | preserve | 656-669 | 662-669 | T26 | heart failure | DiseaseOrSyndrome | 656 | 669 | preserve | 670-678 | 670-678 | T27 | patients | PatientOrDisabledGroup | 670 | 678 | A12 | In 28 heart failure patients (NYHA functional class II) under conventional treatment we measured plasma norepinephrine and efferent postganglionic muscle sympathetic nerve activity (microneurography) at rest and during arterial baroreceptor stimulation and deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. | 650-1035 | 650 | 1,035 | In 28 @SUBJECT$ @PREDICAT$ @OBJECT$ (NYHA functional class II) under conventional treatment we measured plasma norepinephrine and efferent postganglionic muscle sympathetic nerve activity (microneurography) at rest and during arterial baroreceptor stimulation and deactivation induced by stepwise intravenous infusions of phenylephrine and nitroprusside, respectively. |
Fact | preserve | 886-888 | 886-888 | T61 | in | LOCATION_OF | 886 | 888 | preserve | 889-896 | 889-896 | T56 | tissues | Tissue | 889 | 896 | preserve | 864-878 | 864-875 | T54 | angiotensin II | AminoAcidPeptideOrProtein | 864 | 878 | A2 | Crossbreeding of TGR(ASrAOGEN) with a hypertensive transgenic rat strain exhibiting elevated angiotensin II levels in tissues results in a marked attenuation of the hypertensive phenotype. | 759-965 | 759 | 965 | Crossbreeding of TGR(ASrAOGEN) with a hypertensive transgenic rat strain exhibiting elevated @OBJECT$ levels @PREDICAT$ @SUBJECT$ results in a marked attenuation of the hypertensive phenotype. |
Fact | preserve | 1137-1155 | 1144-1155 | T77 | plasma vasopressin | LOCATION_OF | 1,137 | 1,155 | preserve | 1137-1143 | 1137-1143 | T73 | plasma | BodySubstance | 1,137 | 1,143 | preserve | 1144-1155 | 1144-1155 | T74 | vasopressin | AminoAcidPeptideOrProtein | 1,144 | 1,155 | A5 | The observed reduction in plasma vasopressin by 35% may mediate these phenotypes of TGR(ASrAOGEN). | 1105-1215 | 1,105 | 1,215 | The observed reduction in @SUBJECT$ @PREDICAT$ @OBJECT$ by 35% may mediate these phenotypes of TGR(ASrAOGEN). |
Fact | preserve | 465-486 | 471-486 | T40 | brain angiotensinogen | PART_OF | 465 | 486 | preserve | 471-486 | 471-486 | T30 | angiotensinogen | AminoAcidPeptideOrProtein | 471 | 486 | preserve | 465-470 | 465-470 | T29 | brain | BodyPartOrganOrOrganComponent | 465 | 470 | A6 | In these animals, the brain angiotensinogen level is reduced by more than 90% and the drinking response to intracerebroventricular renin infusions is decreased markedly compared with control rats. | 437-651 | 437 | 651 | In these animals, the @OBJECT$ @PREDICAT$ @SUBJECT$ level is reduced by more than 90% and the drinking response to intracerebroventricular renin infusions is decreased markedly compared with control rats. |
Fact | preserve | 86-107 | 92-107 | T8 | brain angiotensinogen | PART_OF | 86 | 107 | preserve | 92-107 | 92-107 | T6 | angiotensinogen | AminoAcidPeptideOrProtein | 92 | 107 | preserve | 86-91 | 86-91 | T5 | brain | BodyPartOrganOrOrganComponent | 86 | 91 | A8 | Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. | 0-108 | 0 | 108 | Blood pressure reduction and diabetes insipidus in transgenic rats deficient in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 48-50 | 48-50 | T7 | in | PROCESS_OF | 48 | 50 | preserve | 29-47 | 38-47 | T2 | diabetes insipidus | DiseaseOrSyndrome | 29 | 47 | preserve | 62-66 | 62-66 | T3 | rats | Mammal | 62 | 66 | A10 | Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. | 0-108 | 0 | 108 | Blood pressure reduction and @SUBJECT$ @PREDICAT$ transgenic @OBJECT$ deficient in brain angiotensinogen. |
Fact | preserve | 154-156 | 154-156 | T18 | in | LOCATION_OF | 154 | 156 | preserve | 157-164 | 157-164 | T11 | tissues | Tissue | 157 | 164 | preserve | 109-120 | 109-120 | T9 | Angiotensin | AminoAcidPeptideOrProtein | 109 | 120 | A11 | Angiotensin produced systemically or locally in tissues such as the brain plays an important role in the regulation of blood pressure and in the development of hypertension. | 109-294 | 109 | 294 | @OBJECT$ produced systemically or locally @PREDICAT$ @SUBJECT$ such as the brain plays an important role in the regulation of blood pressure and in the development of hypertension. |
Fact | preserve | 347-357 | 347-357 | T26 | expressing | PART_OF | 347 | 357 | preserve | 367-380 | 377-380 | T22 | antisense RNA | BiologicallyActiveSubstance | 367 | 380 | preserve | 326-330 | 326-330 | T20 | rats | Mammal | 326 | 330 | A13 | We have established transgenic rats [TGR(ASrAOGEN)] expressing an antisense RNA against angiotensinogen mRNA specifically in the brain. | 295-436 | 295 | 436 | We have established transgenic @OBJECT$ [TGR(ASrAOGEN)] @PREDICAT$ an @SUBJECT$ against angiotensinogen mRNA specifically in the brain. |
Fact | preserve | 1024-1034 | 1024-1034 | T77 | stimulated | STIMULATES | 1,024 | 1,034 | preserve | 1010-1023 | 1010-1023 | T71 | dexamethasone | PharmacologicSubstance | 1,010 | 1,023 | preserve | 1035-1040 | 1035-1040 | T72 | c-Jun | GeneOrGenome | 1,035 | 1,040 | A1 | It was found that dexamethasone stimulated c-Jun expression throughout late gestational period, by approximately 50%. | 986-1116 | 986 | 1,116 | It was found that @SUBJECT$ @PREDICAT$ @OBJECT$ expression throughout late gestational period, by approximately 50%. |
Possible | preserve | 1878-1880 | 1878-1880 | T136 | in | ASSOCIATED_WITH | 1,878 | 1,880 | preserve | 1852-1857 | 1852-1857 | T129 | c-Jun | GeneOrGenome | 1,852 | 1,857 | preserve | 1885-1901 | 1890-1901 | T131 | lung development | OrganOrTissueFunction | 1,885 | 1,901 | A2 | It is possible that c-Jun participates in rat lung development through distinct mechanisms in different developmental stages. | 1832-1970 | 1,832 | 1,970 | It is possible that @SUBJECT$ participates @PREDICAT$ rat @OBJECT$ through distinct mechanisms in different developmental stages. |
Fact | preserve | 962-970 | 966-970 | T69 | rat lung | PART_OF | 962 | 970 | preserve | 966-970 | 966-970 | T67 | lung | BodyPartOrganOrOrganComponent | 966 | 970 | preserve | 962-965 | 962-965 | T66 | rat | Mammal | 962 | 965 | A3 | In the present study, the expression of c-Jun and the influence of dexamethasone on mRNA levels of c-Jun in different developmental stages in the rat lung, was examined. | 804-985 | 804 | 985 | In the present study, the expression of c-Jun and the influence of dexamethasone on mRNA levels of c-Jun in different developmental stages in the @OBJECT$ @PREDICAT$ @SUBJECT$ , was examined. |
Fact | preserve | 1881-1901 | 1890-1901 | T135 | rat lung development | PROCESS_OF | 1,881 | 1,901 | preserve | 1885-1901 | 1890-1901 | T131 | lung development | OrganOrTissueFunction | 1,885 | 1,901 | preserve | 1881-1884 | 1881-1884 | T130 | rat | Mammal | 1,881 | 1,884 | A4 | It is possible that c-Jun participates in rat lung development through distinct mechanisms in different developmental stages. | 1832-1970 | 1,832 | 1,970 | It is possible that c-Jun participates in @OBJECT$ @PREDICAT$ @SUBJECT$ through distinct mechanisms in different developmental stages. |
Fact | preserve | 485-493 | 485-493 | T45 | decrease | INHIBITS | 485 | 493 | preserve | 299-323 | 314-323 | T28 | glucocorticoid receptors | AminoAcidPeptideOrProtein | 299 | 323 | preserve | 498-502 | 498-502 | T36 | mRNA | BiologicallyActiveSubstance | 498 | 502 | A6 | It has been demonstrated that glucocorticoid receptors antagonize the actions of inflammatory mediators through control of the specific DNA binding of the transcriptions factors c-Jun and c-Fos, and also decrease the mRNA and protein levels of these two transcription factors in a number of in vivo and in vitro studies. | 263-607 | 263 | 607 | It has been demonstrated that @SUBJECT$ antagonize the actions of inflammatory mediators through control of the specific DNA binding of the transcriptions factors c-Jun and c-Fos, and also @PREDICAT$ the @OBJECT$ and protein levels of these two transcription factors in a number of in vivo and in vitro studies. |
Fact | preserve | 1381-1404 | 1395-1404 | T100 | dexamethasone treatment | USES | 1,381 | 1,404 | preserve | 1395-1404 | 1395-1404 | T94 | treatment | TherapeuticOrPreventiveProcedure | 1,395 | 1,404 | preserve | 1381-1394 | 1381-1394 | T93 | dexamethasone | PharmacologicSubstance | 1,381 | 1,394 | A7 | Later, on postnatal day 35, when lung maturation and development has been completed, dexamethasone treatment resulted in lowered c-Jun expression, approximately 50%. | 1290-1467 | 1,290 | 1,467 | Later, on postnatal day 35, when lung maturation and development has been completed, @OBJECT$ @PREDICAT$ @SUBJECT$ resulted in lowered c-Jun expression, approximately 50%. |
Fact | preserve | 163-172 | 163-172 | T24 | treatment | TREATS | 163 | 172 | preserve | 147-154 | 147-154 | T16 | therapy | TherapeuticOrPreventiveProcedure | 147 | 154 | preserve | 176-182 | 176-182 | T18 | asthma | DiseaseOrSyndrome | 176 | 182 | A8 | Glucocorticoids are a very potent therapy for the treatment of asthma as well for lung maturation in the prematurely newborn animals and human. | 113-262 | 113 | 262 | Glucocorticoids are a very potent @SUBJECT$ for the @PREDICAT$ of @OBJECT$ as well for lung maturation in the prematurely newborn animals and human. |
Fact | preserve | 785-802 | 794-802 | T55 | alveolar collapse | LOCATION_OF | 785 | 802 | preserve | 785-793 | 785-793 | T52 | alveolar | BodyPartOrganOrOrganComponent | 785 | 793 | preserve | 794-802 | 794-802 | T53 | collapse | PathologicFunction | 794 | 802 | A9 | Additionally, glucocorticoids promote maturation of immature lungs, thereby increasing the production of surfactant proteins which are responsible for prevention of alveolar collapse. | 608-803 | 608 | 803 | Additionally, glucocorticoids promote maturation of immature lungs, thereby increasing the production of surfactant proteins which are responsible for prevention of @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 113-154 | 147-154 | T27 | Glucocorticoids are a very potent therapy | TREATS | 113 | 154 | preserve | 113-128 | 113-128 | T13 | Glucocorticoids | Hormone | 113 | 128 | preserve | 176-182 | 176-182 | T18 | asthma | DiseaseOrSyndrome | 176 | 182 | A11 | Glucocorticoids are a very potent therapy for the treatment of asthma as well for lung maturation in the prematurely newborn animals and human. | 113-262 | 113 | 262 | @SUBJECT$ @PREDICAT$ for the treatment of @OBJECT$ as well for lung maturation in the prematurely newborn animals and human. |
Fact | preserve | 94-102 | 98-102 | T12 | rat lung | PART_OF | 94 | 102 | preserve | 98-102 | 98-102 | T9 | lung | BodyPartOrganOrOrganComponent | 98 | 102 | preserve | 94-97 | 94-97 | T8 | rat | Mammal | 94 | 97 | A13 | Dexamethasone has a biphasic effect on the c-Jun mRNA expression in the fetal and adult rat lung, in vivo. | 0-112 | 0 | 112 | Dexamethasone has a biphasic effect on the c-Jun mRNA expression in the fetal and adult @OBJECT$ @PREDICAT$ @SUBJECT$ , in vivo. |
Fact | preserve | 1795-1815 | 1804-1815 | T127 | rat lung development | PROCESS_OF | 1,795 | 1,815 | preserve | 1799-1815 | 1804-1815 | T124 | lung development | OrganOrTissueFunction | 1,799 | 1,815 | preserve | 1795-1798 | 1795-1798 | T123 | rat | Mammal | 1,795 | 1,798 | A14 | The biphasic effect of dexamethasone on c-Jun expression during rat lung development is of interest. | 1725-1831 | 1,725 | 1,831 | The biphasic effect of dexamethasone on c-Jun expression during @OBJECT$ @PREDICAT$ @SUBJECT$ is of interest. |
Fact | preserve | 864-873 | 864-873 | T68 | influence | INTERACTS_WITH | 864 | 873 | preserve | 909-914 | 909-914 | T63 | c-Jun | GeneOrGenome | 909 | 914 | preserve | 877-890 | 877-890 | T60 | dexamethasone | PharmacologicSubstance | 877 | 890 | A15 | In the present study, the expression of c-Jun and the influence of dexamethasone on mRNA levels of c-Jun in different developmental stages in the rat lung, was examined. | 804-985 | 804 | 985 | In the present study, the expression of c-Jun and the @PREDICAT$ of @OBJECT$ on mRNA levels of @SUBJECT$ in different developmental stages in the rat lung, was examined. |
Fact | preserve | 29-35 | 29-35 | T11 | effect | INTERACTS_WITH | 29 | 35 | preserve | 0-13 | 0-13 | T1 | Dexamethasone | PharmacologicSubstance | 0 | 13 | preserve | 43-48 | 43-48 | T4 | c-Jun | GeneOrGenome | 43 | 48 | A17 | Dexamethasone has a biphasic effect on the c-Jun mRNA expression in the fetal and adult rat lung, in vivo. | 0-112 | 0 | 112 | @SUBJECT$ has a biphasic @PREDICAT$ on the @OBJECT$ mRNA expression in the fetal and adult rat lung, in vivo. |
Fact | preserve | 113-154 | 147-154 | T23 | Glucocorticoids are a very potent therapy | ISA | 113 | 154 | preserve | 113-128 | 113-128 | T13 | Glucocorticoids | Hormone | 113 | 128 | preserve | 147-154 | 147-154 | T16 | therapy | TherapeuticOrPreventiveProcedure | 147 | 154 | A18 | Glucocorticoids are a very potent therapy for the treatment of asthma as well for lung maturation in the prematurely newborn animals and human. | 113-262 | 113 | 262 | @SUBJECT$ @PREDICAT$ @OBJECT$ for the treatment of asthma as well for lung maturation in the prematurely newborn animals and human. |
Fact | preserve | 690-700 | 690-700 | T54 | increasing | STIMULATES | 690 | 700 | preserve | 622-637 | 622-637 | T46 | glucocorticoids | Hormone | 622 | 637 | preserve | 719-729 | 719-729 | T49 | surfactant | BiologicallyActiveSubstance | 719 | 729 | A19 | Additionally, glucocorticoids promote maturation of immature lungs, thereby increasing the production of surfactant proteins which are responsible for prevention of alveolar collapse. | 608-803 | 608 | 803 | Additionally, @SUBJECT$ promote maturation of immature lungs, thereby @PREDICAT$ the production of @OBJECT$ proteins which are responsible for prevention of alveolar collapse. |
Fact | preserve | 1738-1744 | 1738-1744 | T126 | effect | INTERACTS_WITH | 1,738 | 1,744 | preserve | 1748-1761 | 1748-1761 | T120 | dexamethasone | PharmacologicSubstance | 1,748 | 1,761 | preserve | 1765-1770 | 1765-1770 | T121 | c-Jun | GeneOrGenome | 1,765 | 1,770 | A21 | The biphasic effect of dexamethasone on c-Jun expression during rat lung development is of interest. | 1725-1831 | 1,725 | 1,831 | The biphasic @PREDICAT$ of @SUBJECT$ on @OBJECT$ expression during rat lung development is of interest. |
Fact | preserve | 1381-1404 | 1395-1404 | T99 | dexamethasone treatment | ISA | 1,381 | 1,404 | preserve | 1381-1394 | 1381-1394 | T93 | dexamethasone | PharmacologicSubstance | 1,381 | 1,394 | preserve | 1395-1404 | 1395-1404 | T94 | treatment | TherapeuticOrPreventiveProcedure | 1,395 | 1,404 | A22 | Later, on postnatal day 35, when lung maturation and development has been completed, dexamethasone treatment resulted in lowered c-Jun expression, approximately 50%. | 1290-1467 | 1,290 | 1,467 | Later, on postnatal day 35, when lung maturation and development has been completed, @SUBJECT$ @PREDICAT$ @OBJECT$ resulted in lowered c-Jun expression, approximately 50%. |
Fact | preserve | 980-984 | 980-984 | T48 | with | PROCESS_OF | 980 | 984 | preserve | 991-1017 | 1010-1017 | T45 | inflammatory bowel disease | DiseaseOrSyndrome | 991 | 1,017 | preserve | 971-979 | 971-979 | T44 | patients | PatientOrDisabledGroup | 971 | 979 | A1 | Loss of syndecan-1 has been observed in the ulcerated mucosa of patients with inflammatory bowel disease. | 901-1018 | 901 | 1,018 | Loss of syndecan-1 has been observed in the ulcerated mucosa of @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Probable | preserve | 1246-1255 | 1246-1255 | T64 | increases | AUGMENTS | 1,246 | 1,255 | preserve | 1157-1164 | 1157-1164 | T56 | heparin | BiologicallyActiveSubstance | 1,157 | 1,164 | preserve | 1268-1275 | 1268-1275 | T62 | mucosal | Tissue | 1,268 | 1,275 | A2 | We suggest that heparin restores high-affinity receptor binding of basic fibroblast growth, and so increases the rate of mucosal recovery. | 1135-1285 | 1,135 | 1,285 | We suggest that @SUBJECT$ restores high-affinity receptor binding of basic fibroblast growth, and so @PREDICAT$ the rate of @OBJECT$ recovery. |
Fact | preserve | 725-786 | 748-752 | T38 | growth factors, such as basic fibroblast growth factor | ISA | 725 | 786 | preserve | 756-786 | 780-786 | T34 | basic fibroblast growth factor | AminoAcidPeptideOrProtein | 756 | 786 | preserve | 725-739 | 732-739 | T33 | growth factors | BiologicallyActiveSubstance | 725 | 739 | A3 | These include the restoration of high-affinity receptor binding by antiulcerogenic growth factors, such as basic fibroblast growth factor, that normally rely on the presence of heparan sulphate proteoglycans, such as syndecan-1, as co-receptors. | 636-900 | 636 | 900 | These include the restoration of high-affinity receptor binding by antiulcerogenic @OBJECT$ @PREDICAT$ @SUBJECT$ , that normally rely on the presence of heparan sulphate proteoglycans, such as syndecan-1, as co-receptors. |
Fact | preserve | 968-970 | 968-970 | T47 | of | PART_OF | 968 | 970 | preserve | 961-967 | 961-967 | T43 | mucosa | Tissue | 961 | 967 | preserve | 971-979 | 971-979 | T44 | patients | PatientOrDisabledGroup | 971 | 979 | A4 | Loss of syndecan-1 has been observed in the ulcerated mucosa of patients with inflammatory bowel disease. | 901-1018 | 901 | 1,018 | Loss of syndecan-1 has been observed in the ulcerated @SUBJECT$ @PREDICAT$ @OBJECT$ with inflammatory bowel disease. |
Fact | preserve | 944-946 | 944-946 | T46 | in | LOCATION_OF | 944 | 946 | preserve | 961-967 | 961-967 | T43 | mucosa | Tissue | 961 | 967 | preserve | 915-925 | 915-925 | T41 | syndecan-1 | GeneOrGenome | 915 | 925 | A5 | Loss of syndecan-1 has been observed in the ulcerated mucosa of patients with inflammatory bowel disease. | 901-1018 | 901 | 1,018 | Loss of @OBJECT$ has been observed @PREDICAT$ the ulcerated @SUBJECT$ of patients with inflammatory bowel disease. |
Probable | preserve | 814-822 | 814-822 | T39 | presence | COEXISTS_WITH | 814 | 822 | preserve | 756-786 | 780-786 | T34 | basic fibroblast growth factor | AminoAcidPeptideOrProtein | 756 | 786 | preserve | 832-862 | 849-862 | T35 | heparan sulphate proteoglycans | AminoAcidPeptideOrProtein | 832 | 862 | A9 | These include the restoration of high-affinity receptor binding by antiulcerogenic growth factors, such as basic fibroblast growth factor, that normally rely on the presence of heparan sulphate proteoglycans, such as syndecan-1, as co-receptors. | 636-900 | 636 | 900 | These include the restoration of high-affinity receptor binding by antiulcerogenic growth factors, such as @SUBJECT$ , that normally rely on the @PREDICAT$ of @OBJECT$ , such as syndecan-1, as co-receptors. |